January 23, 2018 04:53 PM EST
Pharma

Puma Biotech­nol­o­gy shares tank af­ter CHMP looks ready to hit a red light on ner­a­tinib

John Carroll

Editor & Founder

Six months af­ter Puma Biotech­nol­o­gy won an FDA OK for its can­cer ther­a­py ner­a­tinib, the EMA looks like its prepar­ing to throw up a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times